Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Farouq Qaqish

Family Medicine Omaha, NE Medical Doctor

NPI 1821148826 CMS profile 219075

1010 N 96Th St Ste 200, Omaha, NE 68114

Open in the dashboard

General payments

$6,543

330 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Farouq Qaqish of Omaha, NE is reported in the CMS Open Payments database as having received $6,543 across 330 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $665 28
2022 General $2,004 74
2021 General $1,831 98
2020 General $848 63
2019 General $1,196 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Farouq Qaqish
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Farouq Qaqish were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Farouq Qaqish Family Medicine median Middle half National median
2019 $1,196 $150 $41–$543 $163
2020 $848 $120 $32–$415 $114
2021 $1,831 $137 $35–$551 $132
2022 $2,004 $137 $37–$512 $149
2023 $665 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $1,799 25 payments
  2. Novo Nordisk Inc $950 84 payments
  3. Amgen Inc. $824 38 payments
  4. AbbVie, Inc. $600 38 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $337 16 payments
  6. Lilly USA, LLC $256 22 payments
  7. Amarin Pharma Inc. $189 13 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $145 10 payments
  9. Allergan Inc. $128 10 payments
  10. Mayne Pharma Inc. $125 1 payment
  11. Other $1,192 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $6,543 330 payments
Products named General payments · program years 2019–2023
  1. FARXIGA $1,202 15 payments
  2. BREZTRI $668 9 payments
  3. Ozempic $570 55 payments
  4. Prolia $448 24 payments
  5. EVENITY $412 22 payments
  6. RYBELSUS $400 35 payments
  7. Kerendia $337 16 payments
  8. Saxenda $302 24 payments
  9. Repatha $278 14 payments
  10. NURTEC ODT $227 14 payments
  11. Other $3,076 199 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Family Practice: 1,826

Drug cost

$111

Median for Family Practice: $120,094

Branded share of claims

0%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atorvastatin Calcium Generic 14 $111

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Records

330 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record